AdAlta Ltd

AdAlta is busy working towards a return on its investment in AD-214 and on building the foundations for future growth via its “east to west” cell therapy strategy, a strategy that is getting plenty of attention from both the company’s investor base and potential partners in Asia. CEO and Managing Director, Tim Oldham recently spoke with Tony Locantro of Alto Capital about his confidence in the near term potential for deals for both AD-214 and the cell therapy strategy. | Listen to the interview here: https://lnkd.in/gGZ8Cnzu

AdAlta (ASX:1AD) CEO & Managing Director Dr Tim Oldham joins IPF survivor Bill Van Nierop in the Stockhead TV studio to discuss the devastating impact of Idiopathic Pulmonary Fibrosis (IPF) and how AdAlta's innovative i-body drug candidate, AD-214, is poised to revolutionize treatment | Watch the full interview to learn more: https://lnkd.in/gdeidpsu

AdAlta (ASX:1AD) is pleased to release its 2024 Annual General Meeting Chair Address and CEO Presentation, which detail the recent progress made towards delivering on the Company’s three stated core strategies which are to: ➡ Deliver a new approach to fibrotic disease using AD-214, realising the value created to date through investment in, or licensing by, AdAlta’s fibrosis subsidiary, AdSolis ➡ Enable “East to West” cellular immunotherapies, building the Company’s clinical stage pipeline by providing a pathway for Asian innovation in this transformational field into Western regulated markets through AdAlta’s cell therapy subsidiary, AdCella ➡ Leverage AdAlta’s i-body® platform to continue to discover new therapeutic candidates where traditional antibodies cannot be used. All AGM resolutions were passed with support of greater than 97% of shares voted - we thank shareholders for their continued support and confidence. ASX announcement: https://lnkd.in/g5UJCFAP

AdAlta (ASX:1AD) has announced Ms Michelle Burke and Mr Iain Ross have been appointed to the AdAlta Board as Non-Executive Directors to support the continued execution of the Company’s strategy. - Ms Michelle Burke is an experienced Chair and Non-Executive Director with comprehensive healthcare sector knowledge and specific depth of expertise in strategy, governance, pharmaceuticals and cell therapies.  - Mr Iain Ross has more than 40 years’ experience in the international life sciences sector, including leading board and executive roles in international pharmaceutical and biotechnology companies and brings specific expertise in corporate strategy, financing and capital markets.  - Dr Robert Peach is retiring as Non-Executive Director, after eight years in the role.  AdAlta Chair, Dr Paul MacLeman, commented: “I’m delighted to welcome Michelle and Iain to the AdAlta Board as Non-Executive Directors. I also want to take this opportunity to thank Dr Robert Peach for his extensive contribution to the Company’s scientific and product development over his eight years as a Non-Executive Director. Everyone at AdAlta wishes him every success in his future endeavours.” ASX announcement: https://lnkd.in/gwU9UAzk

The creation and commercialisation of drug candidates originating from AdAlta’s i-body® drug discovery platform is now well-progressed, thanks to the continued efforts of professionals making up the Company’s highly qualified inhouse Scientific Team. They have played critical roles in helping AdAlta evolve its i-body® drug discovery platform. One of these valued individuals is AdAlta Scientist Arfatur Rahman. He is a key member of the analytical team that characterises i-bodies and other proteins to assess their purity and binding strength to target receptors. Describing the important role he plays in ongoing development work on AdAlta’s i-body® drug discovery platform, Arfatur said: “As an Analytical Scientist at AdAlta, my primary focus is to characterize our therapeutic i-body and related proteins. This involves conducting rigorous analytical testing in the lab, ensuring the accuracy and reliability of our data, and maintaining compliance with required standards. “This role is crucial for AdAlta because precise and reliable analytical data are fundamental to the development of safe and effective therapeutics. By ensuring our proteins meet the highest quality standards, I help pre-clinical drug development process.”

AdAlta Ltd (ASX:1AD) CEO and Managing Director, Tim Oldham will present at The Stock Network's ASX Gems investor event Tomorrow, 1 November 💡 Register here to watch and learn: https://lnkd.in/gQJpB3pF

Later this week we will join The Stock Network's Emerging ASX Gems investment conference to outline how we are working to generate shareholder value 💡 Register and watch for free on Friday 1 November: https://lnkd.in/gQJpB3pF

Stockhead's Sarah Hughan chats with AdAlta CEO Tim Oldham about the company’s recent appointments of consultant chief medical officers for its AdCella and AdSolis subsidiaries, as well as the progress of its AD-214 program. Watch the interview here: https://lnkd.in/gkT8KDZ3

AdAlta (ASX:1AD) has released its Appendix 4C cash flow report for the quarter ended 30 September 2024 (Q1 FY25), along with the following financial and operational update: ➡We advanced due diligence and partnering negotiations for both AdSolis (a new approach to fibrosis with AD-214) and AdCella (East to West cellular immunotherapies) ➡We executed our first non-binding term sheet to in-license a product for AdCella, and continue to negotiate additional term sheets across both business units ➡We appointed a deeply experienced clinical advisory board for AD-214 and consultant Chief Medical Officers for both business units ➡We finished the quarter with $1.9m cash and projected inflows of $1m in the December quarter Read more: https://lnkd.in/grqMJJjw

AdAlta (ASX:1AD) has appointed highly experienced physician Kevin Lynch MB BS as Consultant Chief Medical Officer AdCella. He will be an invaluable resource for the latter AdAlta subsidiary as its “East to West” growth strategy continues to be implemented. And the good news does not stop there, with a well-credentialed healthcare professional to join the AdAlta team as Consultant Chief Medical Officer-AdSolis in 2025. The latter individual’s experience will be harnessed to provide extra impetus to that subsidiary’s already well-advanced growth plans | ASX announcement: https://lnkd.in/diyr9b-N